Cellular Origins
A TTP spin-out developing scalable, cost-effective, and efficient manufacture of cell and gene therapies.
Launched in Q1 2023, Cellular Origins is using its proprietary technology to address barriers associated with the manufacture of advanced therapies that are in late-stage development, enabling commercial manufacturing without process change. The platform has been developed for flexibility, with the ability to integrate current workflows and existing instrumentation with future process innovation.
Latest Cellular Origins News & Features
25 January 2024
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze